X

Drug Profile

FZ 006 - Fzata

Alternative Names: FZ-006 - Fzata

Latest Information Update: 29 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Fzata
Class Anti-inflammatories; Gene therapies; Probiotics; Yeasts
Mechanism of Action Gastrointestinal microbiome modulators; Tumour necrosis factor alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Inflammatory bowel diseases

Most Recent Events

29 Aug 2024 Fzata has patent protection for BioPYM technology platform in USA (Fzata pipeline, August 2024)
09 Aug 2024 Preclinical trials in Inflammatory bowel diseases in USA (PO) before August 2024 (Fzata pipeline, August 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com